Negative anti-phospholipase A2 receptor antibody status at three months predicts remission in primary membranous nephropathy

Abstract

Background The value of anti-phospholipase A2 receptor antibody (anti-PLA2R ab) monitoring at 3 months after diagnosis in membranous nephropathy (MN) remains uncertain. Methods We retrospectively examined the outcome on 1 August 2020 of 59 adult patients (age 54 (44, 68) years, 69% male, SCr 1.0 (0.9, 1.3) mg/dL) diagnosed with MN (kidney biopsy, positive serum anti-PLA2R ab). The outcomes were: kidney survival; partial and/or complete remission. Results Most of the studied patients (97%) received immunosuppression, cyclophosphamide regimens were the most frequent (87%), followed by cyclosporine (10%). The median time to remission was 12.0 months and the cumulative remission rates were 34% at 6, 54% at 12, and 73% at 24 months. Forty (69%) patients had negative anti-PLA2R ab at 3 months, they had similar age, serum creatinine, albumin, proteinuria, and treatment with the group with positive ab at 3 months. In the Cox proportional hazard model, three months anti-PLA2R ab negativization (HR 0.4 (95%CI 0.1, 0.9)) was an independent predictor for remission, while baseline hypoalbuminemia (HR 3.0 (95%CI 1.5, 5.7)) was associated with absence of remission. Six (10%) patients died, mostly due to cardiovascular disease and infections. A total of five (9%) patients started dialysis. Mean kidney survival time was 50.3 months and there was no survival difference in relation to baseline anti-PLA2R ab titer ( p .09) or 3 months negativization ( p .8). Conclusions Three months anti-PLA2R ab negativization seems to be a late predictor of remission, and lower serum albumin at diagnosis is an early marker for remission absence. Abbreviations: anti-P LA2R ab, anti-phospholipase A2 receptor antibody; eGFR, estimated glomerular filtration rate; ESKD, end stage kidney disease; MN, membranous nephropathy; NELL-1, neural epidermal growth factor-like 1 protein; RAAS: renin–angiotensin–aldosterone system; RBC: red blood cells; RRT, renal replacement therapy; T HSD7A, thrombospondin type-1 domain containing 7A

Nephrotic Syndrome and Statin Therapy: An Outcome Analysis

“…The hypercoagulable state due to nephrotic syndrome is not well understood and is probably multifactorial [ 17 ]. The most frequent reported abnormalities include reduced levels of natural anticoagulants such as antithrombin III, plasminogen, and protein C and S (due to urinary losses), increased platelet activation, hyperfibrinogenemia, inhibition of plasminogen activation, and the presence of high-molecular-weight fibrinogen in the serum (due to increased liver synthesis) [ 17 , 18 , 19 , 20 ]. Moreover, hypovolemia, diuretic therapy, and corticosteroid treatment can additionally increase the thrombotic risk.…”

The application of podocyte antigen PLA2R and anti-PLA2R antibody in the diagnosis and treatment of membranous nephropathy

“…Early studies emphasized high titer of anti-PLA2R in serum at diagnosis was related to an increased risk of progressive loss of renal function, the rapid transformation from non-nephrotic-range proteinuria to nephrotic-range proteinuria, and a decreased spontaneous remission rate [ 26–31 ]. While some studies found no correlation between the baseline titer of SAb and remission[ 11 , 32 ]. Our analysis showed the presence of SAb was an independent risk factor for no remission.…”

A nomogram prediction model for treatment failure in primary membranous nephropathy

“…The discovery of PLA2Rab in patients with PMN has led to great progress in the diagnosis, disease activity, treatment response evaluation, and prognosis of the disease [ 16 , 17 ]. Dynamic measurement of serum PLA2Rab titer could predict treatment response and disease relapse [ 17 , 18 ].…”